Extracellular Vesicle Core

项目摘要/摘要 罗德岛医院的科布雷干细胞和衰老中心建立了独特的细胞外 水泡核于2019年7月推出。细胞外小泡核心的目标是：1)提供研究社区 在罗德岛医院和罗德岛医院以外的地方，拥有支持以下领域研究的专业知识 细胞外小泡(EV)。2)协助电动汽车实验设计、数据收集、分析和存储，如 以及为国家卫生研究院、行业或基金会的拨款申请做准备。3)加强协作， 罗德岛研究界的翻译研究环境。4)成为一名财务上的 科布雷第三期之后的独立核心设施。主要是细胞外囊泡芯内固定 由两个Thermo WX-40超速离心机、一个Tangenx LHV切向流系统、应用生物系统组成 配备Twister机器人的VIIa™7实时聚合酶链式反应系统，马尔文NanoSight NS500，带有两个激光(405 nm和 488 nm)和光纤细胞系统DUET生物反应器。胞外囊泡核心是一种最先进的设备， 将继续加强医院和大学社区的合作和转化研究。在……里面 与罗德岛医院的临床医生合作，我们的核心做出了重大贡献 探讨EVS作为非侵入性“液体活检”生物标记物的临床意义 疾病治疗的有效性。这导致百时美施贵宝在2020年获得了140万美元的赠款， Quesenberry博士的实验室专门获得了大约35万美元的奖励，用于细胞外小泡核心的研究。 约翰·里根博士从辉瑞公司获得了860,000美元，用于他对EV相关的急性髓系白血病的研究 研究是通过细胞外小泡核心进行的。吉尔·克莱林博士在2022年获得了NIH R01，因为 唾液细胞外小泡作为阿尔茨海默病生物标志物的可行性研究 在接下来的五年里，每年将60,000美元用于细胞外小泡核心。在过去三年里， 细胞外小泡核心已经为来自15个不同学术机构的22名研究人员的18个项目提供了服务 五个机构的科室(布朗大学、罗德岛医院、妇幼医院、 罗德岛大学和普罗维登斯退伍军人医学中心)。这些项目表明， 胞外囊泡核心将继续在支持区域项目和促进 治疗和预防疾病的基础研究和新的治疗方法的转化。

Project Summary/Abstract The COBRE Center for Stem Cells and Aging at Rhode Island Hospital established the unique Extracellular Vesicle Core in July 2019. The aims of the Extracellular Vesicle Core are: 1) To provide the research community at Rhode Island Hospital and outside of Rhode Island Hospital with expertise to support research in the field of Extracellular Vesicle (EV). 2) To assist with EV experimental design, data collection, analysis, and storage, as well as preparation for NIH, industry, or foundation grant submissions. 3) To enhance the collaboration and translational research environment in the Rhode Island research community. 4) To become a financially independent Core facility after Phase 3 of the COBRE. The Extracellular Vesicle Core instrumentation mainly consists of two Thermo WX-40 ultracentrifuges, a Tangenx LHV tangential flow system, Applied Biosystems ViiA™ 7 Real-Time PCR System with Twister robot, a Malvern NanoSight NS 500 with two lasers (405nm and 488nm), and a Fiber Cell Systems duet bioreactor. The Extracellular Vesicle Core is a state-of-the-art facility that will continue to enhance collaboration and translational research in the hospital and university communities. In collaboration with clinical doctors from Rhode Island Hospital, our Core has made significant contributions to investigating the clinical significance of EVs as non-invasive “liquid biopsy” biomarkers for tracking the effectiveness of disease therapy. This resulted in a $1.4 million grant in 2020 from Bristol Myers Squibb, where approximately $350,000 was awarded to Dr. Quesenberry’s lab specifically for the Extracellular Vesicle Core. Dr. John Reagan obtained $860,000 from Pfizer for his study of Acute Myeloid Leukemia, where EV-related research was executed through the Extracellular Vesicle Core. Dr. Jill Kreiling got her NIH R01 in 2022, for the study of the feasibility of using extracellular vesicles in saliva as biomarkers for Alzheimer’s disease where $60,000 per year was committed to the Extracellular Vesicle Core in the next five years. In the last three years, the Extracellular Vesicle Core has serviced 18 projects for 22 investigators from 15 different academic departments at five Institutions (Brown University, Rhode Island Hospital, Women and Infants Hospital, the University of Rhode Island, and Providence VA Medical Center). These projects demonstrate that the Extracellular Vesicle Core will continue to play a crucial role in supporting regional projects and facilitating the basic research and the translation of novel therapeutic approaches to the treatment and prevention of disease.